| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 195 | 165 | 250 | 285 | 208 | 271 | 252 | 330 | 228 | 320 | 261 | 439 |
| Expenses | 116 | 122 | 131 | 146 | 123 | 147 | 135 | 187 | 135 | 177 | 146 | 241 |
| EBITDA | 79 | 44 | 119 | 139 | 85 | 124 | 117 | 143 | 93 | 144 | 115 | 198 |
| Operating Profit % | 36 % | 24 % | 46 % | 47 % | 37 % | 44 % | 44 % | 41 % | 38 % | 43 % | 40 % | 44 % |
| Depreciation | 14 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 64 | 30 | 105 | 124 | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 |
| Tax | 15 | 8 | 27 | 32 | 17 | 29 | 26 | 34 | 20 | 35 | 25 | 43 |
| Net Profit | 49 | 22 | 77 | 92 | 55 | 81 | 78 | 95 | 60 | 96 | 76 | 140 |
| EPS in ₹ | 4.71 | 2.10 | 7.40 | 8.75 | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 |
Concord Biotech
1,748.50
+81.60
(4.90%)
There are new updates from the company1 day ago
Show All
Market Cap
18,292.10 Cr
EPS
29.45
PE Ratio
49.17
Dividend Yield
0.61 %
Industry
Healthcare52 Week High
2,664.00
52 Week Low
1,327.05
PB Ratio
10.08
Debt to Equity
0.01
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Company News
View All News
Concord Biotech Reports Q4 Net Profit of 1.4 Billion Rupees, Recommends Dividend3 days ago
Concord Biotech has reported its Q4 financial results. The company's net profit for the quarter is 1.4 billion rupees, compared to 972 million rupees year-over-year and 741 million rupees quarter-over-quarter. Q4 revenue stands at 4.3 billion rupees, up from 3.2 billion rupees in the same quarter last year. The company has recommended a dividend of 10.70 rupees per equity share.
Concord Biotech Recommends Dividend of 10.70 Rupees per Share3 days ago
Concord Biotech has recommended a dividend of 10.70 rupees per equity share. No additional details about the dividend, such as the fiscal year or record date, were provided in the news snippet.
Concord Biotech Reports Strong Q4 Financial Results3 days ago
Concord Biotech has announced its Q4 financial results. The company's EBITDA increased to 1.9 billion rupees from 1.34 billion rupees year-over-year. The EBITDA margin improved to 44.30% from 42.10% in the same period. Net profit rose to 1.4 billion rupees, up from 972 million rupees year-over-year and 741 million rupees quarter-over-quarter. Revenue for Q4 reached 4.3 billion rupees, compared to 3.2 billion rupees in the previous year.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,677.60 | #1 4,02,512.40 | 35.10 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 42.28 | |
6,612.00 | 1,75,527.80 | 80.12 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.47 | |
1,465.70 | 1,18,372.10 | 22.44 | 26,520.70 | 14.17 | 4,155 | 30.28 | 44.20 | |
3,174.70 | 1,07,446.30 | 55.71 | 10,785.70 | 11.59 | 1,656 | 10.91 | 44.55 | |
1,251.20 | 1,04,407.10 | #1 18.47 | 28,905.40 | 12.36 | 5,578 | 21.14 | 67.52 | |
2,467.70 | 1,01,812.00 | 51.37 | 10,615.60 | 19.57 | 1,942 | -10.91 | 48.86 | |
930.00 | 93,579.80 | 20.04 | 19,831.50 | 13.82 | 3,831 | -0.19 | 63.14 | |
1,957.70 | 89,377.00 | 27.25 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.05 | |
1,147.80 | 66,664.40 | 19.29 | 29,559.20 | 17.55 | 3,169 | -0.50 | 43.00 | |
30,455.00 | 64,714.70 | 45.75 | 6,097.20 | 10.80 | 1,201 | 27.83 | 50.48 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
18.26 %
Net Income Growth
28.32 %
Cash Flow Change
7.91 %
ROE
8.44 %
ROCE
7.81 %
EBITDA Margin (Avg.)
3.94 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2022 | 2023 | 2024 |
| Total Assets | 941 | 1,313 | 1,514 | 1,701 |
| Fixed Assets | 240 | 573 | 593 | 575 |
| Current Assets | 539 | 633 | 728 | 896 |
| Capital Work in Progress | 141 | 74 | 173 | 212 |
| Investments | 199 | 74 | 137 | 246 |
| Other Assets | 361 | 592 | 611 | 668 |
| Total Liabilities | 941 | 1,313 | 1,514 | 1,701 |
| Current Liabilities | 115 | 155 | 192 | 142 |
| Non Current Liabilities | 55 | 54 | 32 | 32 |
| Total Equity | 770 | 1,103 | 1,290 | 1,527 |
| Reserve & Surplus | 761 | 1,094 | 1,280 | 1,516 |
| Share Capital | 10 | 10 | 11 | 11 |
Cash Flow
| Cash Flow | 2020 | 2022 | 2023 | 2024 |
| Net Cash Flow | -1 | -5 | 3 | 12 |
| Investing Activities | -114 | -112 | -158 | -155 |
| Operating Activities | 155 | 208 | 246 | 266 |
| Financing Activities | -43 | -100 | -85 | -99 |
Share Holding
| % Holding | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % |
| FIIs | 0.00 % | 7.30 % | 0.00 % | 6.48 % | 7.11 % | 8.10 % | 8.33 % | 9.35 % |
| DIIs | 4.89 % | 8.18 % | 8.13 % | 8.46 % | 10.40 % | 9.89 % | 9.66 % | 9.16 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.33 % | 6.78 % | 6.76 % | 7.08 % | 7.64 % | 7.33 % | 7.33 % | 6.94 % |
| Others | 37.69 % | 33.66 % | 41.03 % | 33.90 % | 30.76 % | 30.61 % | 30.59 % | 30.47 % |
| No of Share Holders | 3,77,572 | 1,00,927 | 87,486 | 83,296 | 80,737 | 84,298 | 82,004 | 81,219 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.83 | 8.75 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.52 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 May 2025 |  Quarterly Result Announcement | NA | 29 May 2025 | 1,532.10 | 1,635.70 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 2,125.70 | 2,119.00 |
| 11 Nov 2024 | Quarterly Result Announcement | NA | 11 Nov 2024 | 1,812.25 | 1,850.00 |
| 29 Jun 2024 |  Annual General Meeting | NA | 29 Jun 2024 | 1,460.10 | 1,549.05 |
| 22 Jun 2024 |  Dividend | ₹ 8.75 /share | 21 Jun 2024 | 1,460.10 | 1,559.25 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation2 days ago
2 days agoCompliances-Reg.24(A)-Annual Secretarial Compliance3 days ago
3 days agoAppointment Of Auditors3 days ago
3 days agoAppointment of Company Secretary and Compliance Officer3 days ago
3 days agoCorporate Action-Board approves Dividend3 days ago
3 days agoFinancial Result3 days ago
3 days agoBoard Meeting Outcome for Outcome Of Board Meeting Held On 29Th May20253 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoBoard Meeting Intimation for Approval Of Audited Financial Statements For The Quarter And Year Ended March 31 2025.9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMay 13, 2025
May 13, 2025Completion Of Inspection By United States Food And Drug Administration (USFDA) Of Our API Facility At Dholka.May 02, 2025
May 02, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Disclosure Under Of SEBI (LODR) Regulations 2015 Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval To Market Teriflunomide Tablets 7 Mg And 14 Mg In The USApr 08, 2025
Apr 08, 2025Commencement Of Commercial Production At Unit-4 ValtheraMar 25, 2025
Mar 25, 2025Closure of Trading WindowMar 22, 2025
Mar 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Mar 10, 2025Board Meeting Outcome for TO Make INVESTMENT IN M/S CLEAN MAX EVERGLADES PVT LTD FOR INSTALLATION OF HYBRID RENEWABLE ENERGY PLANTMar 04, 2025
Mar 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Mar 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 22, 2025
Feb 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 21, 2025
Feb 21, 2025Intimation About Completion Of Inspection By Ministry Of Food And Drug Safety (MFDS) At Dholka (Unit I) Of The Company.Feb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Feb 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 14, 2025
Feb 14, 2025Integrated Filing (Financial)Feb 13, 2025
Feb 13, 2025 Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Feb 13, 2025Board Meeting Outcome for Financial Results For The Period Ended 31 December 2024Feb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2025
Jan 31, 2025Board Meeting Intimation for Financial ResultsJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-AcquisitionJan 16, 2025
Jan 16, 2025Announcement under Regulation 30 (LODR)-AcquisitionJan 16, 2025
Jan 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 11, 2025
Jan 11, 2025Announcement under Regulation 30 (LODR)-AcquisitionDec 12, 2024
Dec 12, 2024Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2024
Nov 19, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2024
Nov 14, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2024
Nov 14, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2024
Nov 11, 2024Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 11, 2024
Nov 11, 2024Board Meeting Outcome for Outcome Of Board Meeting Held Today, November 11, 2024 - Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 11, 2024
Nov 11, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Nov 06, 2024Board Meeting Intimation for Board Meeting Intimation For Approve The Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2024Nov 06, 2024
Nov 06, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 10, 2024
Oct 10, 2024Closure of Trading WindowSep 25, 2024
Sep 25, 2024Technical Indicators
RSI(14)
Neutral 70.38
ATR(14)
Volatile 66.33
STOCH(9,6)
Neutral 79.04
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 30.01
ADX(14)
Weak Trend 20.55
UO(9)
Bearish 63.71
ROC(12)
Uptrend And Accelerating 16.03
WillR(14)
Overbought -12.39
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Edelweiss Large & Mid Cap Direct Plan-Growth | 65497 | 0.27% | -0.38% | -0.35% | Apr 2025 | |
 Invesco India Multicap Fund Direct-Growth | 226042 | 0.91% | -0.37% | -0.32% | Apr 2025 | |
 SBI Healthcare Opportunities Fund Direct Plan-Growth | 400000 | 1.65% | 0.36% | 0.75% | Apr 2025 | |
 Baroda BNP Paribas Large & Mid Cap Fund Direct - Growth | 180000 | 1.79% | -0.29% | -0.23% | Apr 2025 | |
 UTI Small Cap Fund Direct - Growth | 203613 | 0.73% | -0.28% | -0.24% | Apr 2025 | |
| Baroda BNP Paribas Multi Cap Fund Direct-Growth | 281863 | 1.58% | -0.23% | -0.14% | Apr 2025 | |
| Baroda BNP Paribas Innovation Fund Direct - Growth | 122471 | 1.90% | -0.21% | 0.58% | Apr 2025 | |
| Invesco India Manufacturing Fund Direct-Growth | 70219 | 1.38% | -0.20% | -0.14% | Apr 2025 | |
 DSP Healthcare Fund Direct - Growth | 489774 | 2.55% | -0.18% | 0.07% | Apr 2025 | |
| Invesco India Aggressive Hybrid Fund Direct - Growth | 42148 | 0.98% | -0.17% | -0.13% | Apr 2025 | |
| Edelweiss Small Cap Fund Direct - Growth | 264705 | 0.95% | -0.14% | -0.11% | Apr 2025 | |
| Baroda BNP Paribas ELSS Tax Saver Fund Direct-Growth | 61800 | 1.06% | -0.14% | -0.08% | Apr 2025 | |
| Baroda BNP Paribas Balanced Advantage Fund Direct - Growth | 300000 | 1.10% | -0.14% | 0.07% | Apr 2025 | |
| Baroda BNP Paribas Business Cycle Fund Direct - Growth | 36000 | 0.97% | -0.13% | -0.03% | Apr 2025 | |
| Invesco India Flexi Cap Fund Direct - Growth | 125889 | 0.69% | -0.13% | -0.12% | Apr 2025 | |
 ITI Flexi Cap Fund Direct - Growth | 64017 | 0.92% | -0.12% | -0.10% | Apr 2025 | |
| Invesco India Smallcap Fund Direct - Growth | 330193 | 0.81% | -0.12% | -0.11% | Apr 2025 | |
| Invesco India ELSS Tax Saver Fund Direct-Growth | 158906 | 0.89% | -0.12% | -0.28% | Apr 2025 | |
 HSBC Small Cap Fund Direct-Growth | 853962 | 0.88% | -0.11% | -0.08% | Apr 2025 | |
 Bandhan Midcap Fund Direct-Growth | 74821 | 0.73% | -0.11% | -0.10% | Apr 2025 | |
| Baroda BNP Paribas Equity Savings Fund Direct - Growth | 8427 | 0.47% | -0.10% | -0.05% | Apr 2025 | |
| Edelweiss ELSS Tax Saver Fund Direct -Growth | 17540 | 0.67% | -0.10% | -0.07% | Apr 2025 | |
 Union Small Cap Fund Direct-Growth | 82786 | 0.86% | -0.10% | -0.15% | Apr 2025 | |
| Edelweiss Mid Cap Direct Plan-Growth | 297646 | 0.49% | -0.09% | -0.05% | Apr 2025 | |
| Baroda BNP Paribas Retirement Fund Direct - Growth | 15100 | 0.62% | -0.09% | -0.06% | Apr 2025 |
About Concord Biotech
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Listing Date
18 Aug, 2023(1 Years,
15 days)
Chairperson NameSUDHIR JAIRAM VAID
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
